Department of Cardiology, The Heart Center, Rigshospitalet, University of Copenhagen, Denmark.
Department of Cardiology, The Heart Center, Rigshospitalet, University of Copenhagen, Denmark.
Cardiovasc Revasc Med. 2020 Jul;21(7):843-848. doi: 10.1016/j.carrev.2019.11.002. Epub 2019 Nov 9.
We aimed to relate the amount of jeopardized myocardium to mortality in shocked patients presenting to the catheterization laboratory with ST-elevation myocardial infarction (STEMI) and cardiogenic shock.
In contrast with historical data and previous professional guidance, contemporary randomized data suggest that multi-vessel revascularization in such patients does not improve survival; mechanistic insight is incomplete.
Clinical databases identified cases of STEMI and shock triaged for primary percutaneous coronary intervention (PPCI) in Eastern Denmark from June 2011 to December 2014 (n = 128). British Cardiovascular Intervention Society (BCIS)-1 jeopardy scores were calculated from angiography. The study endpoint was 30-day mortality.
Median lactate values were 6.0 [2.9-10.7] mmol/L. 30-day mortality was 53.9%. 68% of patients had multi-vessel coronary disease. Median pre-PCI BCIS-1 myocardial jeopardy scores were 8 [6-10]. After multiple logistic regression increasing age (p = 0.008; odds ratio [OR] 1.06), lactate values (p = 0.017; OR 1.02), mechanical ventilation (p = 0.011; OR 1.25) and a systolic blood pressure ≤ 90 mmHg at end-case (p = 0.005; OR 1.26) were predictive of 30-day mortality. Post-PPCI culprit vessel TIMI 3 flow was associated with reduced mortality (p < 0.001; OR 0.66). There was no association between pre-PCI jeopardy scores and the primary endpoint.
In patients with STEMI and shock, myocardial jeopardy scores do not relate to patient outcomes. Jeopardy scores may be applied to existing datasets in order to understand why multi-vessel revascularization does not lead to the anticipated clinical benefits in cardiogenic shock.
我们旨在探讨 ST 段抬高型心肌梗死(STEMI)并心原性休克患者接受导管室治疗时,心肌危险程度与死亡率之间的关系。
与历史数据和先前的专业指南相反,当代随机数据表明,此类患者的多血管血运重建并不能提高生存率;机制上的认识尚不完全。
临床数据库确定了 2011 年 6 月至 2014 年 12 月丹麦东部接受直接经皮冠状动脉介入治疗(PPCI)的 STEMI 合并休克患者(n=128)的病例。从血管造影中计算英国心血管介入学会(BCIS)-1 危险评分。研究终点为 30 天死亡率。
中位乳酸值为 6.0[2.9-10.7]mmol/L。30 天死亡率为 53.9%。68%的患者有多血管冠状动脉疾病。中位数 PCI 前 BCIS-1 心肌危险评分 8[6-10]。经多因素逻辑回归分析,年龄(p=0.008;比值比[OR]1.06)、乳酸值(p=0.017;OR 1.02)、机械通气(p=0.011;OR 1.25)和最终病例时收缩压≤90mmHg(p=0.005;OR 1.26)与 30 天死亡率相关。PCI 后罪犯血管 TIMI 3 级血流与死亡率降低相关(p<0.001;OR 0.66)。PCI 前危险评分与主要终点之间无相关性。
在 STEMI 合并休克的患者中,心肌危险评分与患者预后无关。危险评分可应用于现有数据集,以了解为什么多血管血运重建在心源性休克中未带来预期的临床获益。